ALGORITHM FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTION

Despite a significant number of publications devoted to the care of patients with chronic heart failure (CHF), a practicing doctor is not always easy to navigate in the use of medicines and indications for high-tech methods of treatment in these patients. The largest evidence base is currently accumulated in patients with CHF with a reduced left ventricular ejection fraction (CHFrEF), which is characterized by a significant decreasing in the quality of life, decreased/lost ability to work, disability of patients and high mortality. This article details all the essential medicines used for therapy of CHFrEF, the sequence and practical aspects of their prescribing in accordance with contemporary guidelines. The issue of treating patients with CHF refractory to standard therapy, including with the help of a new class of drugs from the group of angiotensin receptor neprilysin inhibitor, cardiac resynchronization therapy, implantation of cardioverter-defibrillators and application of devices for mechanical circulatory support and heart transplantation is considered. The publication is illustrated by tables, figures, diagrams, which makes it accessible for understanding and memorizing. 

1. Braunwald E., Heart failure. JACC Heart Fail. 2013; 1(1): 1-20.

2. McMurray J.J. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2012; 14(8): 803-69.

3. Go A.S. et al., Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014; 129(3): e28-e292.

4. Mozaffarian, D. et al. Heart Disease and Stroke Statistics-2015 Update: A Report From the American Heart Association. Circulation. 2014.

5. Фомин И.В., Беленков Ю.Н. , Мареев В.Ю. Распространенность ХСН в Европейской части Российской Федерации — данные ЭПОХА-ХСН (часть 2). Сердечная недостаточность. 2006; 7(3): 3-7. Fomin I.V., Belenkov Yu.N., Mareev V.Yu. Prevalence of CHF in the European part of the Russian Federation — data of EPOCHA-CHF. Heart failure. 2006; 7(3): 3-7 [in Russian].

6. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная недостаточность. 2013; 7: 379-472. Mareev, V.Yu., F.T. Ageev, and G.P. Arutyunov, National recomme ndations of OSSN, RKO and RNMOT on diagnosis and treatment of CHF (fourth revision), in Journal of Heart Failure. 2013; 7: 379-472 [in Russia n].

7. Stewart S. et al. An economic analysis of specialist heart failure nurse management in the UK; can we afford not to implement it? Eur. Heart. J. 2002; 23(17): 1369-78.

8. Hunt S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management o f Heart Failure). J. Am. Coll. Cardiol. 2005; 46(6): e1-82.

9. Ross J.S. et al. Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail. 2010; 3(1): 97-103.

10. Giamouzis G. et al. Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. J. Card. Fail. 2011; 17(1): 54-75.

11. Nichols M. et al. Cardiovascular disease in Europe 2014: epidemiological update. Eur. Heart J. 2014; 35(42): 2929.

12. Резник Е.В. Особенности поражения орга нов-мишеней у больных с хронической сердечной недостаточностью. Диссертация на соискание ученой степени доктора медицинских наук. Москва. 2016; 500. Reznik E.V. Features o f the damages of target organs in patients with chronic heart failure. Dissertation for the degree of Doctor of Medical Sciences. Moscow. 2016; 500 [in Russian].

13. Maggioni A.P. et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur. J. Heart Fail. 2013; 15(7): 808-17.

14. . The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data met aanalysis. Eur. Heart J. 2012; 33(14): 1750-7.

15. Hummel S.L. et al. Thirty-day outcomes in Medicare patients with heart failure at heart transplant centers. Circ. Heart Fail. 2010; 3( 2): 244-52.

16. Ponikowski P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart fai lure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2016; 18(8): 891-975.

17. Мареев В.Ю. et al. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Общество специалистов по сердечной недостаточности: Москва. 2016; 92. Mareev V.Yu. et al. Clinical recommendations for Chronic heart failure (CHF). Society for Heart Failure S pecialists: Moscow. 2016; 92 [in Russian].